Cite
HARVARD Citation
Ng, P. et al. (n.d.). Preclinical efficacy of BDTX-4933, a brain penetrant MasterKey inhibitor targeting oncogenic BRAF Class I/II/III mutations. European journal of cancer. pp. S86-. [Online].
This is an interim version of our Electronic Legal Deposit Catalogue-eJournals and eBooks while we continue to recover from a cyber-attack.
Ng, P. et al. (n.d.). Preclinical efficacy of BDTX-4933, a brain penetrant MasterKey inhibitor targeting oncogenic BRAF Class I/II/III mutations. European journal of cancer. pp. S86-. [Online].